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Spleen tyrosine kinase (SYK) plays a major role in inflamma-
tion and in adaptive immune responses and could therefore con-
tribute to the neuroinflammation observed in various neurode-
generative diseases. Indeed, previously we have reported that
SYK also regulates -amyloid (A) production and hyperphos-
phorylationofTauprotein involved in these diseases.Moreover,
SYKhyperactivation occurs in a subset of activatedmicroglia, in
dystrophic neurites surrounding A deposits, and in neurons
affected by Tau pathology both in individuals with Alzheimer’s
disease (AD) and inADmousemodels. SYK activation increases
Tau phosphorylation and accumulation, suggesting that SYK
could be an attractive target for treating AD. However, the
mechanism by which SYK affects Tau pathology is not clear. In
this study, using cell biology and biochemical approaches, along
with immunoprecipitation and immunoblotting, quantitative
RT-PCR, and ELISAs, we found that SYK inhibition increases
autophagic Tau degradation without impacting Tau produc-
tion. Using neuron-like SH-SY5Y cells, we demonstrate that
SYK acts upstream of the mammalian target of rapamycin
(mTOR) pathway and that pharmacological inhibition or
knockdown of SYK decreases mTOR pathway activation and
increases autophagic Tau degradation. Interestingly, chronic
SYK inhibition in a tauopathymousemodel profoundly reduced
Tau accumulation, neuroinflammation, neuronal and synaptic
loss, and also reversed defective autophagy. Our results further
suggest that the SYK up-regulation observed in the brains of
individuals with AD contributes to defective autophagic clear-
ance leading to the accumulation of pathogenic Tau species.
These findings further highlight SYK as a therapeutic target for
the treatment of tauopathies and other neurodegenerative pro-
teinopathies associated with defective autophagic clearance.
Alzheimer’s disease (AD)2 is the most prevalent form of
dementia and is characterized by the pathological accumula-
tion of Tau andA aggregates. Proteinmisfolding, aggregation,
and accumulation constitute a pathological hallmark of neuro-
degenerative proteinopathies. Many studies have suggested
that neurodegeneration is, at least partly, caused by a dysfunc-
tional degradation of proteins that are prone to aggregate. In
fact, an impaired autophagic clearance of macromolecules has
been widely accepted to be a major contributor to various neu-
rodegenerative diseases (1–4) by promoting the accumulation
of misfolded proteins. The mammalian target of rapamycin
(mTOR) is known to regulate autophagy (5). The members of
the mTOR pathway, including phosphatidylinositol-4,5-bis-
phosphate 3-kinase (PI3K), 3-phosphoinositide-dependent
protein kinase 1 (PDK1), protein kinase B (Akt), tuberous scle-
rosis 1/2 (TSC1/2), Ras homolog-enriched in brain (Rheb),
mTOR, and ribosomal protein S6 kinase (S6K), thereby also
indirectly control the autophagic degradation of proteins. AD
and frontotemporal lobar degeneration (FTLD) share the accu-
mulation of Tau as a common underlying pathology. In human
AD and FTLD cases, as well as inmousemodels of AD and pure
tauopathy, autophagy has been found to be decreased (6–8)
and to contribute to the pathological accumulation of Tau
aggregates. Impaired autophagy has been linked to an overac-
tive mTOR pathway, which acts as a regulator of autophagy
initiation and lysosomal degradation, thereby controlling the
autophagic flux (5, 9).
More specifically, in the frontotemporal dementia and par-
kinsonism linked to chromosome 17 (FTDP-17) mouse model
that overexpresses mutant Tau (Tg Tau P301S), direct inhibi-
tion of mTOR with either rapamycin or temsirolimus attenu-
ated Tau pathology (10, 11). Furthermore, stimulation of
autophagy by trehalose or by the overexpression of the tran-
scription factor EB were both shown to be efficient in reducing
neurodegeneration and mitigating tauopathy in Tg Tau P301S
mice (12, 13) suggesting that inhibiting mTOR may have ther-
apeutic value for the treatment of tauopathies.
The nonreceptor spleen tyrosine kinase (SYK) is known as a
modulator of the immune response. SYK has been shown to be
involved in B-cell receptor and T-cell receptor signaling.
Hence, SYK inhibition has been proposed as a therapeutic
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approach for various diseases, including leukemia, autoim-
mune disorders, and allergies (14–17).
SYK has also been suggested to phosphorylate microtubules
in B-cells (18) and to be involved in neuron-like differentiation
and extracellular signal-regulated kinase (ERK) activation in
embryonal carcinoma P19 cells (19). Furthermore, pharmaco-
logical SYK inhibition has been found to stabilize microtubules
in paclitaxel-resistant tumor cells (20).
SYK has been shown to mediate the activation of microglial
cells induced by A oligomers (21, 22), whereas SYK inhibition
has been shown to prevent A-mediated neurotoxicity in vitro
(21). A subsequent study also demonstrated that SYK was the
mediator of the A-induced elevated cytokine production,
including interleukin 1 (IL-1) and tumor necrosis factor 
(TNF) which is responsible for increased iNOS expression
resulting in apoptosis in primarymouse neuronal cultures (23).
In addition, it has been suggested that SYK contributes to
microglial dysfunction in AD (24).
In our previous studies, we identified SYK as a novel target
for the treatment of AD (25, 26). We found that SYK inhibition
can decrease A production and Tau hyperphosphorylation in
vitro and in vivo in mouse models of AD and tauopathy follow-
ing an acute treatment (25), in part, by promoting the phos-
phorylation of GSK-3 at the inhibitory Ser-9 site and reducing
BACE-1 expression (25).
More recently, we have shown that SYK activation, as mea-
sured by p-SYK (Tyr-525/526) levels, is largely increased in dys-
trophic neurites and microglia of A-overexpressing mouse
models of AD (Tg PS1/APPsw, Tg APPsw) and in neurons of a
mouse model of tauopathy (Tg Tau P301S) displaying patho-
logical Tau species, whereas the neurons of WT animals
showed no activation of SYK (26), suggesting that SYK plays a
key role in the formation of AD pathological lesions. Similarly,
we observed an increased SYK activation in dystrophic neurites
and in neurons affected by the Tau pathology in human AD
specimens (26). Interestingly, we have shown that SYK activa-
tion promotes Tau accumulation but does not affect Tau
expression suggesting that SYK may affect Tau clearance (26).
In this study, we further investigated the SYKmolecular mech-
anisms that drive Tau accumulation both in vitro and in vivo.
We show that SYK is a key regulator of themTOR pathway and
that SYK inhibition, as well as suppression of SYK expression,
leads to an inhibition of the mTOR pathway, resulting in
increased autophagic Tau degradation. Moreover, we show
that chronic SYK inhibition lowers pathological Tau accu-
mulation in Tg Tau P301S mice by inhibiting hyperactive
mTOR. Furthermore, chronic SYK inhibition reduces the
levels of pro-inflammatory cytokines and neuronal and syn-
aptic loss and improves locomotor deficits in Tg Tau P301S
mice. These data not only provide further evidence for an
important role of SYK in the pathogenesis of AD and the
development of tauopathies but also illustrate that pharma-
cological SYK inhibition may represent a promising thera-
peutic strategy for the treatment of AD and other neurode-
generative proteinopathies associated with a defective
autophagic clearance of misfolded proteins.
Results
Our previous data suggest that SYK may regulate Tau clear-
ance since we have observed that SYK up-regulation promotes
Tau accumulation without affecting Tau expression (26). As
Tau clearance is known to be regulated via autophagy, we
therefore investigated the possible impact of SYK inhibition
on the mTOR pathway and autophagic degradation of Tau in
SH-SY5Y cells.
SYK inhibition decreases p-Tau, as well as total Tau levels, and
reverses the effects of the Akt activator SC79 on themTOR
pathway
We show that SYK inhibition using the selective SYK inhib-
itor BAY61-3606 (BAY61) (27) dose-dependently decreases
p-Tau (Ser-396/404) levels (Fig. 1,A and B) and total Tau levels
in SH-SY5Y cells (Fig. 1, A and B).
In parallel with the reduction of total Tau levels induced by
SYK inactivation with BAY61, a dose-dependent inhibition of
several members of the mTOR pathway was observed (Fig. 1, B
andC). Comparedwith untreated control cells, p-Akt (Ser-473)
and p-S6K (Thr-389 and Thr-412) levels were significantly
lower following SYK inhibition (Fig. 1C, p 0.01). As expected,
the Akt activator SC79 stimulated the mTOR pathway, as it
increases the phosphorylation levels of p-S6K (Thr-389 and
Thr-412) and p-mTOR (Ser-2448) significantly (Fig. 1C, p 
0.01). We show that SYK inhibition reverses the effects of the
Akt activator and decreases the phosphorylation levels of p-Akt
(Ser-473), p-S6K (Thr-389 and Thr-412), and p-mTOR (Ser-
2448) induced by SC79 (Fig. 1C, p 0.001). Interestingly, base-
line levels of mTOR phosphorylation remained unchanged fol-
lowing SYK inhibition, but elevated mTOR phosphorylation
following SC79 activation was brought back to baseline levels
following SYK inhibition, suggesting that SYK inhibition can
antagonize dysregulated mTOR phosphorylation (Fig. 1C).
In addition, we have differentiated SH-SY5Y cells with retinoic
acid and BDNF, as described previously by Encinas et al. (28),
and assessed the effects of SYK inhibition on the Tau level and
on the mTOR/autophagy pathway. We show that SYK inhibi-
tion with BAY61-3606 also results in decreased total Tau,
p-AKT, p-S6K, and p-mTOR levels in differentiated SH-SY5Y
cells (Fig. S1B), confirming the data obtained with undifferen-
tiated SH-SY5Y cells.
SYK inhibition reverses the effects of themTOR activator
MHY1485 andmimics the effects of themTOR inhibitor
KU0063794
We further investigated the effects of SYK inhibition on the
mTOR pathway and determined whether SYK inhibition can
overcome the impact of the mTOR activator MHY1485. We
also tested the effects of the mTOR inhibitor KU0063794 on
phosphorylated and total Tau levels in SH-SY5Y cells to deter-
mine whether direct mTOR inactivation can mimic the effects
of SYK inhibition. mTOR activation with MHY1485 signifi-
cantly increased p-mTOR (Ser-2448), p-S6K (Thr-389 and
Thr-412), and p-Tau (Ser-396/404) levels, whereasmTOR inhi-
bition with KU0063794 significantly decreased p-Akt (Ser-
473), p-S6K (Thr-389 and Thr-412), and p-mTOR (Ser-2448)
levels compared with the untreated control cells (Fig. 2, A and
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B). The levels of t-Tau and p-Tau (Ser-396/404) were also sig-
nificantly lower in cells that were treatedwith themTOR inhib-
itor than in cells that were treated with the mTOR activator
(Fig. 2, A and B). In fact, mTOR inhibition appears to be mim-
icking the effects of SYK inhibition on the mTOR pathway
(Figs. 1 and 2). Interestingly, SYK inhibition was able to antag-
onize the increased p-Tau (Ser-396/404), p-S6K (Thr-389 and
Thr-412), p-mTOR (Ser-2448), and p-Akt (Ser-473) levels
induced byMHY1485 (Fig. 2, C andD). A trend for an increase
in total Tau levels was observed following 24 h of treatment
with the mTOR activatorMHY1485, which was also prevented
by SYK inhibition (Fig. 2,C andD) showing that SYK inhibition
can overcome the effects of a stimulation of the mTOR path-
way. Interestingly, SYK inhibition prevents the stimulation of
mTOR by the mTOR activator MHY1485 due to the mecha-
nism of action of MHY1485. In fact, MHY1485 facilitates the
phosphorylation of mTOR at Ser-2448 by AKT (29) and there-
fore requires AKT to be active to allow mTOR activation (30).
We show that SYK inhibition prevents PI3K/AKT signaling and
suppresses mTOR phosphorylation at Ser-2448. Therefore,
whenSYK is inhibited,AKT is also suppressedandcannotphos-
phorylate mTOR even in the presence of MHY1485. We
observed a greater inhibition of S6K phosphorylation than an
inhibition of mTOR phosphorylation with BAY61. This could
be explained by the fact that SYK can stimulate JNK, whereas
SYK inhibition also reduces JNK (31, 32). It has to be noted that
Figure 1. SYK inhibition decreases p-Tau as well as total Tau levels and reverses the effects of the Akt activator SC79 on the mTOR pathway. A,
representative Western blottings depicting p-Tau (Ser-396/404) and total Tau are shown. Western blot chemiluminescent signals were quantified by densi-
tometry and normalized to actin. B, histogram represents the quantification of Western blottings probed with antibodies against p-Tau (Ser-396/404), t-Tau,
p-Akt (Ser-473), p-p70S6K (Thr-389), p-mTOR (Ser-2448), normalized to actin, following a 24-h treatment of SH-SY5Y cells with 100 nM and 1, 2.5, 5, or 10M of
the SYK inhibitor BAY61. ANOVA with post hoc Bonferroni test revealed significant decreases starting at 1 M. C, representative Western blottings depicting
p-mTOR (Ser-2448), p-S6K (Thr-389 and Thr-412), and p-Akt (Ser-473) are shown.Western blot chemiluminescent signals were quantified by densitometry and
normalized to actin. D, histogram represents the quantification of p-mTOR (Ser-2448), p-S6K (Thr-389 and Thr-412), and p-Akt (Ser-473) following a 24-h
treatment of SH-SY5Y cells with 5 M of the SYK inhibitor BAY61-3606 and 20 M of the Akt activator SC79 and a combination thereof. ANOVA with post hoc
Bonferroni test revealed significantly decreased p-Akt (Ser-473) (p 0.01) andp-S6K (Thr-389 and Thr-412) (p 0.01, p 0.001) levels following SYK inhibition
(n 3) and also significantly increased p-mTOR (Ser-2448) (p 0.01) and p-S6K (Thr-389 and Thr-412) (p 0.01) levels following Akt activation. SYK inhibition
reverses these effects significantly in the double treatment (n 3 for each treatment condition).
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JNK can also directly phosphorylate S6K (33) and also affects
the degradation of S6K. Therefore, the effects that we are
observing on S6K phosphorylation could be mediated by the
combined suppression of JNK and mTOR following SYK inhi-
bition, thus explaining why overall SYK inhibition has a greater
impact on S6K phosphorylation than on mTOR phosphoryla-
tion. We also observed an inhibition of Akt following mTOR
inhibition with KU0063794. The effect of the mTOR inhibitor
KU0063794 on Akt phosphorylation is expected and has been
described before (34). In fact, Akt (Ser-473) is a known sub-
strate of mTOR, and mTOR has been shown to regulate Akt
phosphorylation at that site (35–38).
In addition, we show thatmTOR inhibitionwith KU0063794
significantly decreases p-Tau (Ser-396/404) and t-Tau levels in
SH-SY5Y cells stably overexpressing SYK (Fig. S1) that exhibit
increased Tau levels compared with control cells (26). These
data suggest that mTOR inhibition can overcome the impact of
SYK up-regulation on t-Tau levels. In summary, these results
show that SYK inhibition and direct mTOR inhibition have
similar effects on the mTOR pathway and Tau levels. Further-
more, SYK inhibition can reverse the effects of mTOR activa-
tion on members of the mTOR pathway and Tau, thereby
underlining a role of SYK as an upstream modulator of the
mTOR pathway and regulator of autophagic Tau degradation.
Figure 2. SYK inhibition reverses the effects of themTOR activatorMHY1485 andmimics the effects of themTOR inhibitor KU0063794. SH-SY5Y
cells were treated for 24 h with 4 M of the mTOR activator MHY1485 or 1–2 M of the mTOR inhibitor KU0063794 (A and B) or a combination of 6–12
M of the mTOR activator MHY1485 and 5 M of the SYK inhibitor BAY61-3606 (C and D). A, representative Western blottings depicting p-mTOR
(Ser-2448), p-S6K (Thr-389 and Thr-412), p-Akt (Ser-473), p-Tau (Ser-396/404), and t-Tau are shown. B, Western blot chemiluminescent signals were
quantified by densitometry, normalized to actin, and presented as histograms. ANOVA with post hoc Bonferroni test revealed significantly increased
p-mTOR (Ser-2448) (p 0.05), p-S6K (Thr-389 and Thr-412) (p 0.01, p 0.0001), and p-Tau (Ser-396/404) (p 0.05) levels compared with untreated
control cells following mTOR activation by MHY1485, whereas mTOR inhibition by KU0063794 decreased p-S6K (Thr-389 and Thr-412) (p 0.0001 and
p  0.01) and p-Akt (Ser-473) (p  0.01) levels significantly compared with control (n  3 for each treatment condition). C, representative Western
blottings depicting p-mTOR (Ser-2448), p-S6K (Thr-389 and Thr-412), p-Akt (Ser-473), p-Tau (Ser-396/404) ,and t-Tau are shown. D, Western blot
chemiluminescent signals were quantified by densitometry, normalized to actin, and presented as histograms. ANOVA with post hoc Bonferroni test
revealed that the combination of the mTOR activator and the SYK inhibitor results in significantly decreased p-mTOR (Ser-2448) (p  0.01), p-S6K
(Thr-389 and Thr-412) (p 0.01), p-Akt (Ser-473) (p 0.01), and p-Tau (Ser-396/404) (p 0.01) levels compared with untreated control cells (n 3 for
each treatment condition).
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SYK inhibition increases the autophagic flux and decreases
Tau levels in the presence of the lysosomal inhibitor
chloroquine
Having shown that SYK acts upstream of mTOR and
thereby influences the autophagic degradation of Tau, we
investigated whether SYK inhibition could impact the
autophagic flux by quantifying the amount of the microtu-
bule-associated protein 1A/1B-light chain (LC3). During
autophagy initiation, soluble cytosolic LC3-I gets lipidated,
and the resulting LC3-II becomes associated with the in-
side and outside of autophagosomal membranes (39). After
the fusion of autophagosomes with lysosomes, LC3-II is
degraded. Hence, the ratio of unlipidated LC-I to lipidated
LC3-II can be used to measure the autophagic flux, the rate
of autophagy initiation, and lysosomal degradation (40, 41).
Because an increase in LC3-II levels following drug treat-
ment could be indicative of either an increase in autophagy
initiation or a decrease in lysosomal degradation, we em-
ployed a lysosome inhibitor (chloroquine (CQ)) to deter-
mine the rate of autophagy initiation, as described previously
(40, 42). CQ accumulates in the lysosomes and raises their
pH. Thereby, CQ decreases the functionality of lysosomal
proteases and inhibits the fusion of lysosomes and autopha-
gosomes. Therefore, CQ allows the observation of the con-
version rate of LC3-I to LC3-II (autophagy initiation) by lim-
iting the degradation of LC3-II. We treated SH-SY5Y cells
for 24 h with two different doses of CQ (100 and 200 M)
alone or in combination with 5 M of the SYK inhibitor
BAY61. CQ treatment significantly increased p-S6K (Thr-
389), p-mTOR (Ser-2448), and t-Tau levels (Fig. 3, A and B)
showing an inhibition of lysosomal t-Tau degradation. As
expected, CQ treatment also increased the ratio of LC3-II/I
by decreasing the degradation of LC3-II (Fig. 3C). Impor-
tantly, the increased levels of p-S6K (Thr-389), p-mTOR
(Ser-2448), and t-Tau levels induced by CQ were signifi-
cantly reduced following SYK inhibition (Fig. 3, A and B).
The ratio of LC3II/I was further increased after a double
treatment with CQ and BAY61 compared with CQ alone
(Fig. 3C). Because the degradation of LC3-II is inhibited by
CQ, the additional increase of LC3-II observed in cells
treated with CQ and the SYK inhibitor suggests that SYK
inhibition accelerates the conversion of LC3-I into LC3-II
and therefore stimulates the autophagic flux. The increased
degradation of t-Tau following the co-treatment with CQ
and the SYK inhibitor compared with CQ alone (Fig. 3) sug-
gests that SYK inhibition not only increases autophagy initi-
ation but may also increase the lysosomal degradation of
Tau, which was antagonized by CQ.
SYK inhibition does not affect Tau translation or transcription
Because SYK acts upstream of the mTOR pathway and the
downstream kinase S6K is known to be involved in translation,
we investigated whether SYK inhibition and S6K inhibition
could impact Tau translation (Fig. 4). We show that the reduc-
tion in t-Tau protein level following SYK inhibition is not
caused by a reduction of t-Tau transcription as measured by
Figure 3. SYK inhibition increases the autophagic flux and decreases tau levels in the presence of the lysosomal inhibitor chloroquine. SH-SY5Y cells
were treated for 24 h with 100–200 M of the lysosomal inhibitor chloroquine (CQ) or a combination of 100–200 M CQ and 5 M of the SYK inhibitor
BAY61-3606.A, representativeWesternblottingsdepictingp-mTOR (Ser-2448), p-S6K (Thr-389 andThr-412), p-Tau (Ser-396/404), t-Tau, andLC3-I/II are shown.
B and C, Western blot chemiluminescent signals were quantified by densitometry, normalized to actin, and presented as histograms. B, ANOVAwith post hoc
Bonferroni test revealed significantly increasedp-mTOR (Ser-2448) (p0.001), p-S6K (Thr-389) (p0.001), and t-Tau (p0.05) levels comparedwithuntreated
control cells following lysosomal inhibition by CQ, whereas a combination of CQ and the SYK inhibitor reverses the effects of CQ, leading to significantly
decreasedp-mTOR (Ser-2448) (p 0.01), p-S6K (Thr-389 andThr-412) (p 0.0001,p 0.05), and t-Tau (p 0.01) levels comparedwithCQalone (n 4 for each
treatment condition). C, ANOVA with post hoc Bonferroni test revealed that the combination of the lysosomal and the SYK inhibitor results in significantly
increased autophagic flux compared with CQ alone (CQ (100 M) BAY61, p 0.05, CQ (200 M) BAY61, p 0.0001), as measured by LC3II/I, whereas the
LC3-I levels were not altered significantly (n.s.) (n 4 for each treatment condition).
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RT-PCR (mRNA) (Fig. 4).We then assessed protein translation
in SH-SY5Y cells that were treated for 24 h with either 5 or 10
M of the SYK inhibitor BAY61 or 5 or 10 M of the S6K inhib-
itor PF4708671 or 20 M cycloheximide (inhibitor of protein
translation used as a positive control) (Fig. 4A). Protein trans-
lation was quantified using the SUrface SEnsing of Translation
(SUnSET) techniques (43) by monitoring puromycin incorpo-
ration in newly-synthesized proteins. Both SYK inhibition and
S6K inhibition significantly decreased puromycin incorpora-
tion, particularly in proteins of higher molecular weight (Fig.
4A). This may suggest a general effect of SYK inhibition on
translation that is possiblymediated by S6K inhibition, because
SYK inhibition completely prevents S6K phosphorylation and
because a direct S6K inhibitionmimics the impact of SYK inhi-
bition on protein translation (Fig. 4, A and B). However, isola-
tion of newly synthesized proteins by immunoprecipitation
using an anti-puromycin antibody followed by Western blot
analysis using a total Tau antibody (DA9) to quantify the
amount of nascent Tau reveals no impact of SYK inhibition
(Fig. 4, C and D) on Tau protein translation. In addition,
t-Tau and 3R mRNA levels in SH-SY5Y cells are not
impacted by SYK inhibition with 5 M BAY61 for 4, 8, 12,
and 24 h (Fig. 4, E and F) showing that SYK inhibition does
not affect Tau expression at the mRNA level. These data
further demonstrate that the decrease in t-Tau level,
observed following SYK inhibition, is mainly caused by an
increase in autophagic Tau degradation, rather than a
decreased level of Tau translation or transcription.
In a subsequent experiment, we tested the effects of S6K inhi-
bition by PF4708671 on the mTOR pathway and Tau degrada-
Figure 4. SYK inhibition does not alter transcription or translation levels of Tau in vitro. A and B, SUrface SEnsing of Translation (SUnSET) technique (43)
was used to assess the impact of SYK inhibition on protein translation. SH-SY5Y cells were treatedwith 5–10M of the SYK inhibitor BAY61-3606 or 5–10M of
the S6K inhibitor PF4708671 for 24 h or with cycloheximide for 5 h. Cells were then treated for 1 h with 10 g/ml puromycin. Levels of newly synthesized
proteins containing puromycin were then detected by Western blotting using an anti-puromycin antibody. A, representative Western blottings depicting
puromycin andactin are shown.B,Westernblot chemiluminescent signalswerequantifiedbydensitometry, normalized to actin, andpresentedashistograms.
ANOVAwithpost hocBonferroni test revealed total levels of translation are significantly reduced followingSYK inhibition (5Mp0.05; 10Mp0.01) or S6K
inhibition (10M p 0.01) or following cycloheximide treatment (20M p 0.0001) (n 4 for each treatment condition). C andD, anti-puromycin antibodies
and protein A-magnetic beads were used for immunoprecipitation of the cell lysate following treatment with 5 M BAY61. Western blotting analysis with
anti-puromycin and anti-t-tau antibodies, quantification (as in A and B) and subsequent unpaired t test (D) revealed no significant difference in total tau
translation levels following SYK inhibition, whereas the puromycin levels were significantly decreased (p 0.05) (n 3 for each treatment condition). E and F,
mRNA levels of total Tau and 3R Tau weremeasured by RT-PCR following different durations of treatment with 5M of the SYK inhibitor BAY61-3606. ANOVA
with post hoc Bonferroni test revealed no significant difference of taumRNA levels treated with BAY61-3606 for 4, 8, 12, or 24 h versus untreated control (n
4 for each treatment condition).
Spleen tyrosine kinase blocks autophagic Tau degradation
J. Biol. Chem. (2019) 294(36) 13378–13395 13383
 at O
PEN
 U
N
IV
ERSITY
 on O
ctober 3, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
tion. S6K inhibition using 10MPF4708671 leads to significant
reduction in p-mTOR (Ser-2448) and p-S6K (Thr-389 andThr-
412) levels (Fig. 5, A and B). p-Akt (Ser-473) levels remain
unchanged following S6K inhibition. This could imply the
existence of a feedbackmechanism following S6K inhibition on
the mTOR pathway, as S6K is a downstream kinase of mTOR.
In fact, S6K has been shown to phosphorylate mTOR (Ser-
2448) (44), and the reductions in mTOR phosphorylation that
we observed with PF4708671 are consistent with that observa-
tion. A nonsignificant trend for a decrease p-Tau (Ser-396/404)
and t-Tau levels was observed in SH-SY5Y cells (Fig. 5,A andC)
following 24 h of treatment with the S6K inhibitor suggesting
that the S6K inhibition observed following SYK inactivation
does not play a major role in the increased Tau clearance
induced by SYK inhibition.
In summary, these in vitro data show an upstream modula-
tory role of SYK on the mTOR pathway in SH-SY5Y cells and
suggest that SYK is amajor kinase that regulates the autophagic
degradation of Tau. Our data suggest that SYK inhibition
increases Tau degradation in SH-SY5Y cells by inhibiting the
mTOR pathway and increasing the autophagic flux.
Suppression of SYK expressionmimics pharmacological
inhibition of SYK and decreases total Tau levels
To validate the data obtained following pharmacological
inhibition of SYK with BAY61 and to ensure that the effects
observed were mediated by SYK inhibition, we knocked
down SYK by stably overexpressing a SYK shRNA in
SH-SY5Y cells. As expected, a significant decrease in total
SYK (t-SYK) (Fig. 6) was observed in the SYK knockdown
SH-SY5Y cells compared with control SH-SY5Y cells that
were stably transfected with a nonsense shRNA using the
same vector. We show that SYK knockdown significantly
decreases p-mTOR (Ser-2448), p-S6K (Thr-389), p-Akt (Ser-
473), p-Tau (Ser-396/404) , and t-Tau levels (Fig. 6, A and B)
mimicking the effects of the SYK inhibitor BAY61 in
SH-SY5Y cells. Interestingly, LC3-I and LC3-II were both
significantly decreased in the SYK knockdown cells, al-
though their ratio remained unchanged (Fig. 6A). These
data suggest that genetic suppression of SYK expression
leads to an increased autophagy initiation (LC3-I conversion
to LC3-II) and an enhancement of lysosomal LC3-II degra-
Figure5. S6K inhibitionbyPF4708671has similar effectsasSYK inhibitionon themTORpathwayandtau levels.SH-SY5Ycellswere treated for 24hwith
5–10 M of the S6K inhibitor PF4708671. Western blottings were quantified, normalized to actin, and expressed relative to the untreated control cells. A,
representativeWestern blottings depicting p-mTOR (Ser-2448), p-S6K (Thr-389 and Thr-412), p-Akt (Ser-473), p-Tau (Ser-396/404), and t-Tau are shown. B and
C, Western blot chemiluminescent signals were quantified by densitometry, normalized to actin, and presented as histograms. B, ANOVA and post hoc
Bonferroni test revealed that p-mTOR (Ser-2448) (p 0.001) and p-S6K (Thr-389 and Thr-412) (p 0.001, p 0.01) levels were reduced significantly compared
with control following S6K inhibition. p-Akt levels remained unchanged. C, total Tau and p-Tau (Ser-396/404) were slightly reduced at the highest dose of
PF4708671 (n 4 for each treatment condition). D, representative Western blottings and quantification thereof depicting the fold change of t-Tau following
treatment with 20 and 30 M of the S6K inhibitor PF4708671.
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dation. To further test this hypothesis, we treated both con-
trol and SYK knockdown cells for 24 h with 200 M of the
lysosomal inhibitor CQ. In the presence of CQ, the SYK
knockdown cells exhibited a significantly increased ratio of
LC3-II/I as observed in SH-SY5Y cells treated with CQ and
BAY61, implying an increased autophagic flux and suggest-
ing that SYK may impact both the autophagy initiation and
lysosomal degradation (Fig. 6C).
Overall, our data show that the knockdown of SYKmimics
the data obtained following pharmacological inhibition of
SYK in SH-SY5Y cells resulting in an inhibition of key mem-
bers of the mTOR pathway and further establishes a key
role of SYK as an upstreammodulator of the mTOR pathway
(Fig. 7).
Chronic SYK inhibition reduces p-SYK and t-SYK levels in Tg
Tau P301Smice, rescues neuronal and synaptic loss, and
decreasesmTOR activity
Following these in vitro studies, we investigated the effects of
chronic SYK inhibition on Tau levels, neurodegeneration,
inflammation, and behavior in vivo using a tauopathy mouse
model. The 30-week-old Tg Tau P301S mice and age-matched
wildtype (WT) littermates were treated for 12 weeks with 20
mg/kg of the SYK inhibitor BAY61 or PBS as a vehicle control
(Fig. 8A). As we demonstrated previously (26), SYK activation,
as measured by p-SYK (Tyr-525/526) levels, is significantly
higher inTgTauP301S–PBSmice comparedwithWTcontrols
(Fig. 8B). Importantly, the chronic treatment with the SYK
Figure 6. SYK knockdown mimics pharmacological inhibition of SYK and decreases total Tau levels. Lentiviral vectors expressing SYK-specific
shRNAs or nonsense control shRNAs were used to stably knock down SYK gene expression in SH-SY5Y cells. A and B, representative Western blottings
depicting p-mTOR (Ser-2448), p-S6K (Thr-389 and Thr-412), t-SYK, and LC3-I/II, as well as p-Akt (Ser-473), p-Tau (Ser-396/404), and t-Tau are shown.
Western blot chemiluminescent signals were quantified by densitometry, normalized to actin, and presented as histograms. Unpaired t tests revealed
that in SYK knockdown cells in which t-SYK was decreased significantly (p  0.0001), p-mTOR (Ser-2448) (p  0.05), p-S6K (Thr-389) (p  0.05), p-Akt
(Ser-473) (p 0.0001), t-Tau (p 0.0001), and p-Tau (Ser-396/404) (p 0.0001) levels were also significantly decreased (n 6). LC3-I and LC3-II levels
were significantly decreased in SYK knockdown cells compared with control (p  0.0001), but the ratio of both remains unchanged. C, both SYK
knockdown and control cells were treated for 24 h with 200 M of the lysosomal inhibitor CQ. Representative Western blottings depicting t-SYK and
LC3-I/II are shown. Western blot chemiluminescent signals were quantified by densitometry, normalized to actin, and presented as histograms.
Unpaired t tests revealed that in SYK knockdown cells in which t-SYK was decreased significantly (p  0.0001), the ratio of LC3-II/I was significantly
increased (p  0.001) (n  6 for each treatment condition).
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inhibitor significantly reduced the elevated levels of p-SYK
(Tyr-525/526) (Fig. 8B) confirming target engagement follow-
ing treatment with BAY61. t-SYK levels were also increased in
Tg Tau P301S–PBS mice compared with WT littermates and
were significantly decreased following chronic SYK inhibition
(Fig. 8B).
The neuron-specific protein NeuN (45) has been used previ-
ously as a marker for neurodegeneration or neuronal loss (46,
47). Neuronal loss revealed by a reduction in NeuN has been
described previously in Tg Tau P301Smice (8, 12). Post-synap-
tic density-95 (PSD-95) has been shown to promote the stabi-
lization of synapses and to regulate synaptic transmission (48–
50). In addition, it has been established that levels of PSD-95 are
significantly reduced in TgTau P301Smice and reflect synaptic
loss (51, 52). We therefore investigated whether chronic inhi-
bition of SYK with BAY61 was able to affect NeuN and PSD-95
levels in Tg Tau P301S mice. Our data show that PSD-95 and
NeuN levels were reduced in Tg Tau P301S–PBS mice com-
pared with WT littermates (Fig. 8) confirming previous obser-
vations (51, 52). Interestingly, the chronic treatment with the
SYK inhibitor was able to considerably increase PSD-95 and
NeuN levels in Tg Tau P301S mice (Fig. 8B), suggesting that
SYK inhibition prevents neuronal and synaptic loss in Tg Tau
P301S mice.
The p-mTOR (Ser-2448) levels were significantly increased
in Tg Tau P301S–PBS mice compared with WT littermates
Figure 7. Schematic depiction of the role of SYK in themTORpathway and autophagy. The schematic describes the role of SYK in themTORpathway and
autophagic tau degradation. ThemTORpathway, including PI3K, PDK1, Akt, TSC1/2, Rheb,mTOR, and S6K, and their role in regulation of autophagy havebeen
well-described in the literature (for review see Ref. 82). Our previous studies revealed SYK as an upstream regulator of PKA, GSK-3, and PI3K (25). PI3K is
recognized as an upstreammember of themTORpathway, andGSK3- is known to regulate raptor, which is part of themTOR complex I. In this study, we used
different activators and inhibitors of members of the mTOR pathway (see legend) to elucidate the effect of SYK inhibition on the mTOR pathway. Our
mechanistic experiments lead to the conclusion that SYK acts upstream of themTOR pathway and thereby influences the activity levels of different members
of that pathway and the autophagic degradation of Tau. mTOR itself is known to inhibit autophagy. mTOR prevents the transcription factor EB (TFEB) from
entering the nucleus, thereby preventing the transcription of autophagy-related genes (ATGs), leading to a decreased autophagy initiation. Furthermore, the
kinase S6K downstream of mTOR is involved in translation. Our results show that SYK inhibition leads to a decreased activation of the mTOR pathway and
results in an increased autophagic flux (LC3-I to LC3-II conversion), leading to an increased lysosomal degradation of Tau.
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(Fig. 8C), suggesting there might be an associated reduction in
autophagy. As observed in our in vitro experiments, SYK inhi-
bition was able to significantly decrease the abnormally high
p-mTOR (Ser-2448) levels observed in Tg Tau P301S brains
bringing them back to the levels observed in WT littermates
(Fig. 8C). The p-S6K (Thr-389) levels were slightly elevated in
Tg Tau P301S–PBS mice compared with WT littermates, and
chronic SYK inhibitionwas able to significantly decrease p-S6K
(Thr-389) levels in the brain of Tg Tau P301S mice (Fig. 8C),
confirming an inhibition of the mTOR pathway. Interestingly,
the lysosomal membrane–associated protein 1 (LAMP-1) was
also significantly increased in Tg Tau P301S–PBS mice com-
pared with WT littermates, whereas chronic SYK inhibition
was able to significantly reduce LAMP-1 levels in the brains of
Tg Tau P301S mice (Fig. 8C).
Chronic SYK inhibition reduces Tau accumulation and
improvesmotor performance in Tg Tau P301Smice
Following the assessment of target engagement, we investi-
gated the effects of chronic SYK inhibition on detergent-solu-
ble and -insoluble Tau levels in the brains of Tg Tau P301S
mice. We found that chronic SYK inhibition over a 12-week
period significantly reduced the levels of t-Tau, p-Tau (Ser-
396/404 and Ser-202), and Tau oligomers (TOC1) in the deter-
gent-insoluble fraction of brain homogenates compared with
PBS-treated Tg Tau P301S mice. A trend for a reduction in
detergent insoluble p-Tau (Ser-231) and Tau conformers
(MC1)was also observed following chronic SYK inhibition (Fig.
9A). Detergent-soluble total Tau levels were also reduced fol-
lowing SYK inhibition compared with PBS-treated Tg Tau
P301S mice; however, only soluble p-Tau (Ser-231) was signif-
icantly impacted by SYK inhibition (Fig. 9B).
In addition to the reducedTauburden, a significant improve-
ment in locomotor coordination, measured by a decreased
latency to fall in the rotarod apparatus, was observed in Tg Tau
P301S mice following chronic inhibition of SYK (Fig. 9C).
Chronic SYK inhibition decreases neuroinflammation in Tg
Tau P301Smice
Because SYK is known to be involved in the activation of
microglia (21, 22), we investigated the effects of chronic SYK
inhibition on neuroinflammation in Tg Tau P301S mice. As
expected, the microglial marker Iba-1 was significantly in-
creased in Tg Tau P301S–PBS mice compared with WT litter-
mates (Fig. 10A). Chronic SYK inhibition was able to decrease
Iba-1 levels significantly in Tg Tau P301S mice (Fig. 10A). We
also investigated the levels of iNOS, which is known to be ele-
vated in activated microglia (53). iNOS levels were found to be
significantly increased in Tg Tau P301S–PBS mice compared
with WT littermates (Fig. 10A). Chronic SYK inhibition
appeared to significantly lower iNOS levels in Tg Tau P301S
mice (Fig. 10A). Levels of the astrocytic marker, glial fibrillary
acidic protein (GFAP), were similar with or without BAY61
treatment in WT and Tg Tau P301S mice (Fig. 10A). We also
quantified by ELISA the amount of various pro-inflamma-
tory cytokines in the brain. Overall, pro-inflammatory cyto-
kine levels for most of the cytokines analyzed were higher in
Tg Tau P301S–PBSmice compared withWT littermates and
decreased in the Tg Tau P301S–BAY61 treatment group
(Fig. 10B).
In summary, these data show that chronic SYK inhibition
over a course of 12 weeks leads to significant reduction in neu-
ronal and synaptic loss, inhibition of hyperactive mTOR,
decreased Tau burden, improvedmotor performance, and sup-
pression of neuroinflammation in Tg Tau P301S mice. Impor-
tantly, the decreased t-Tau and p-mTOR levels observed sug-
gest that in vivo SYK inhibition also triggers the degradation of
Tau via an autophagy-dependentmechanism similar to the one
observed in vitro.
Figure8.ChronicSYK inhibition reducesp-SYKandt-SYK levels inTgTau
P301S mice, rescues neuronal and synaptic loss, and decreases mTOR
activity. A, 30-week-old Tg Tau P301S mice and wildtype (WT) littermates
were treated for 12 weeks with either PBS (control) or 20 mg/kg of the SYK
inhibitor BAY61-3606 (administered i.p.)WT-PBS (n11),WT-BAY61 (n11),
Tg Tau P301S–PBS (n 11), and Tg Tau P301S–BAY61 (n 12). Animals were
tested for motor performance using the Rotarod every 14 days. B and C,
PSD-95 levels weremeasured by ELISA. Levels of p-SYK, t-SYK, NeuN, p-mTOR
(Ser-2448), p-S6K (Thr-389), and LAMP-1 were obtained by dot blots whose
chemiluminescent signals were quantified and normalized to -tubulin lev-
els. All values are presented relative to WT-PBS (control). B, ANOVAwith post
hoc Bonferroni test revealed that SYK activation, as measured by p-SYK (Tyr-
525/526) levels, was significantly increased in Tg Tau P301S–PBS mice com-
paredwithWT controls (p 0.0001). Chronic treatmentwith 20mg/kg of the
SYK inhibitor BAY61-3606 reduced these levels significantly (p  0.0001).
t-SYK levels were also significantly reduced following treatment in Tg Tau
P301S mice (p 0.01). PSD-95 and NeuN levels were significantly increased
(p 0.05) following treatment with BAY61 in Tg Tau P301S mice compared
with untreated (PBS) controls. C, ANOVA with post hoc Bonferroni test
revealed thatmTORactivation, asmeasuredbyp-mTOR (Ser-2448) levels,was
significantly increased in Tg Tau P301S–PBSmice comparedwithWT controls
(p  0.001). Chronic treatment with 20 mg/kg of the SYK inhibitor BAY61-
3606 reduced these levels significantly (p  0.01). LAMP-1 levels were also
significantly increased in Tg Tau P301S–PBSmice comparedwithWT controls
(p  0.0001). Chronic treatment with 20 mg/kg of the SYK inhibitor BAY61-
3606 reduced these levels significantly (p  0.001). The treatment also
reduced p-S6K (Thr-389) levels significantly in Tg Tau P301S mice (p 0.01).
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Discussion
Our previous data have shown that SYK is up-regulated in
the brain of AD patients and in mouse models of AD (26). In
particular, we have shown that SYK is overactivated in neurons
affected by the Tau pathology and that SYK up-regulation pro-
motesTau accumulationwithout affectingTau expression (26).
In this study, we show that SYK inhibition as well as genetic
suppression of SYK expression lower total Tau levels in
SH-SY5Y cells without impacting Tau expression at themRNA
level or Tau protein translation suggesting that other mecha-
nisms are responsible for the increased Tau clearance observed
following SYK inhibition. Therefore, we investigated the possi-
ble effects of SYK inhibition on the mTOR pathway and
autophagic degradation of Tau in SH-SY5Y cells and in Tg Tau
P301S following a chronic treatment with a SYK inhibitor as
autophagy plays a pivotal role in Tau degradation (54).
We show for the first time that SYK can regulate the mTOR
pathway in neuronal-like SH-SY5Y cells and promote the
autophagic clearance of Tau. These data are consistent with
previous studies that have highlighted the role of SYK on the
mTOR pathway in immune and cancerous cells (55–61).
Autophagy is crucial for maintaining the intracellular home-
ostasis by regulating the turnover of misfolded or damaged
proteins and organelles and eliminating dysfunctional com-
ponents. A decreased functionality of the autophagic degra-
dation system has been linked to aging and neurodegenera-
tive diseases (1–4, 62–66). Many studies have now
demonstrated the beneficial effects of mTOR inhibition in
mouse models of AD and tauopathy, resulting in increased
autophagy and in an amelioration of Tau pathologies (11–
13), suggesting that manipulating the mTOR pathway may
constitute an attractive therapeutic strategy for the treat-
ment of neurodegenerative proteinopathies.
In this study, we demonstrate that SYK inhibition leads to an
increased total Tau degradation via the mTOR-dependent
autophagy pathway, whereas transcription and translation lev-
els of Tau remain unchanged. By examining the effects of SYK
inhibition on members of the mTOR pathway, using selective
inhibitors and activators of themTOR pathway in combination
with the SYK inhibitor BAY61, we confirmed that SYK acts
upstream of the mTOR pathway and thereby modulates
autophagy in a neuron-like cell line (SH-SY5Y). We show, for
example, that the dysregulation of the mTOR pathway, as well
as the Tau accumulation induced by the AKT stimulator SC79
or by MHY1485 (a direct activator of mTOR), can be reversed
by SYK inhibition. We also confirm that inhibition of mTOR
with KU0063794 can mimic the effects of SYK inhibition and
increase the clearance of Tau in SH-SY5Y cells. In addition, the
treatment with CQ in combination with the SYK inhibitor
revealed an increased autophagic flux following SYK inhibition,
as measured by an increase in the LC3II/I ratio, as well as
mTOR and S6K inhibition and increased Tau degradation. To
validate the data obtained with the SYK inhibitor BAY61, we
also generated an SH-SY5Y cell line in which SYK has been
stably knocked down. We confirm that Tau degradation is
stimulated and that the mTOR pathway is also inhibited in this
SYK knockdown cell line, showing that the effects of BAY61 on
Tau clearance are recapitulated by genetic suppression of SYK
expression and are therefore attributable to an inhibition of
SYK.
Figure9.ChronicSYK inhibition reduces insolubleandsolubleTau levels
and improvesmotor performance in Tg Tau P301Smice. 30-Week-old Tg
Tau P301Smice andwildtype (WT) littermateswere treated for 12weekswith
either PBS (control) or 20 mg/kg of the SYK inhibitor BAY61-3606 (adminis-
tered i.p.) Tg Tau P301S–PBS (n 11), Tg Tau P301S–BAY61 (n 12). A, deter-
gent (M-PER)-insoluble, and B, detergent (M-PER)-soluble Tau levels were
obtained by dot blots whose chemiluminescent signals were quantified, nor-
malized to-tubulin levels, andexpressedas a fold changeof theaverageTau
values quantified in placebo-treated Tg Tau P301S mice. A, unpaired t tests
revealed that insoluble total Tau levels (p 0.05), as well as p-Tau (Ser-396/
404 (p 0.05) and Ser-202 (p 0.001)) and Tau oligomers (TOC1) (p 0.01)
were significantly reduced following chronic SYK inhibition. B, soluble p-Tau
(Ser-231) levels were reduced significantly following treatment with BAY61.
C, animals’ motor performance was tested using the rotarod every 14 days
following the initiation of the BAY61 treatment. Two-way ANOVA with post
hoc Bonferroni revealed a significant difference inmotor performance for the
last day (R6) between the control (Tg Tau P301S–PBS) mice and the mice
treated with the SYK inhibitor. Motor performance of Tg Tau P301S–BAY61
mice improved significantly between the first and last day (R1–R6) of assess-
ment but not in control.
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We then assessed the impact of a chronic SYK inhibition
with BAY61 in a pure model of tauopathy, Tg Tau P301S mice.
SYK inhibition was initiated in 30-week-old Tg Tau P301S
mice. By that age, Tg Tau P301S mice already show significant
Tau accumulation and hyperphosphorylation as well as neuro-
inflammation and synaptic loss (51). We treated Tg Tau P301S
mice for 12 weeks with BAY61 and observed that the treatment
was well-tolerated and was not affecting the weight of the mice
or the weight of major organs (data not shown). Behavioral
analyses revealed that locomotor performances of the Tg Tau
P301S mice were improved following SYK inhibition in the
rotarod apparatus. Our biochemical characterizations of the
brains of these mice confirmed our previous findings that SYK
activation is increased in Tg Tau P301S mice (26), and they
reveal target engagement following BAY61 treatment, as the
autophosphorylation of SYK in the activation loop of the kinase
was significantly reduced in Tg Tau P301S mice treated with
BAY61. We found that mTOR activation was increased in Tg
Tau P301S mice compared with WT littermates, suggesting
that autophagy could be decreased and contribute to patholog-
ical Tau accumulation in Tg Tau P301S mice. Tg Tau P301S
mice treated with the SYK inhibitor showed a reduction of
mTOR activation confirming the in vitro data showing the
impact of SYK on the regulation of the mTOR pathway.
We analyzed the impact of SYK inhibition on the accumula-
tion of Tau pathogenic species in the soluble and insoluble
detergent fractions of TgTauP301S brain homogenates. Deter-
gent-insoluble Tau species have been shown to generally con-
tain Tau aggregates that contribute to neurodegeneration (66,
67), whereas hyperphosphorylated Tau in the detergent-solu-
ble fraction has previously been associated with synaptic loss
(68). We found that t-Tau levels, as well as p-Tau (Ser-396/404
and Ser-202) levels and Tau oligomers (TOC1), were signifi-
cantly decreased in the detergent-insoluble fraction, following
SYK inhibition in Tg Tau P301Smice. Given that mTOR phos-
phorylation was reduced following SYK inhibition in Tg Tau
P301Smice, these data further suggest that the decreased accu-
mulation of the pathological Tau species observed results in
part from an increased Tau degradation via the restored
mTOR–autophagy pathway.
It is well-known that tauopathies, including AD and fronto-
temporal dementia with parkinsonism-17 (FTDP-17), lead to
Figure 10. Chronic SYK inhibition decreases microgliosis and reduces pro-inflammatory cytokines in Tg Tau P301S mice. 30-Week-old Tg Tau P301S
mice andwildtype (WT) littermateswere treated for 12weekswith either PBS (control) or 20mg/kg of the SYK inhibitor BAY61-3606 (administered i.p.)WT-PBS
(n 11), WT-BAY61 (n 11), Tg Tau P301S–PBS (n 11), and Tg Tau P301S–BAY61 (n 12). A, Iba-1, GFAP, and iNOS levels were obtained by dot blots whose
chemiluminescent signals were quantified, normalized to -tubulin levels, and expressed as a fold change of the average tau values quantified in placebo-
treated Tg Tau P301S mice. ANOVA with Bonferroni tests revealed that Iba-1 (p  0.05) and iNOS (p  0.0001) levels were significantly increased in Tg Tau
P301S–PBSmice comparedwithWT-PBSmice suggesting thatmicroglia are activated in Tg Tau P301Smice. Chronic SYK inhibition significantly reduced Iba-1
(p 0.01) and iNOS (p 0.0001) levels in Tg Tau P301S mice. GFAP levels did not differ significantly between the groups. B and C, brain cytokine levels were
quantified by ELISA and normalized to total protein levels. B and C, Kruskal-Wallis test revealed that the elevated brain cytokine levels observed in Tg Tau
P301S–PBS (control)micewere significantly reduced following chronic SYK inhibition (TgTauP301S–BAY61) for interferon- (p0.05), IL-2 (p0.05), IL-5 (p
0.05), and IL12p70; KC/GRO levels were significantly increased (p 0.05) in Tg Tau P301S–PBS mice compared with WT controls.
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neurodegeneration. In mouse models of tauopathy, including
the Tg Tau P301S mice, reduced levels of the neuronal marker
NeuN have been found and interpreted as evidence of neuro-
degeneration (12, 13). Interestingly, it has been shown (13) that
NeuN levels were restored in Tg Tau P301S mice following
stimulation of autophagy. In addition, it was found that stimu-
lation of autophagy in Tg Tau P301S mice can decrease insolu-
bleTau, aswell as p-Tau (AT100 andPHF-1) levels (12, 13). The
results of our study are in line with these findings. We also
observed decreased levels of synaptic and neuronal markers
PSD-95 and NeuN in Tg Tau P301S mice, which were consid-
erably increased following chronic SYK inhibition, suggesting
that SYK inhibition can prevent neurodegeneration and synap-
tic loss induced by Tau pathogenic species in Tg Tau P301S
mice.
Neuroinflammation has been shown previously to be in-
creased inTgTauP301Smice (51, 69) and is likely to exacerbate
the neurodegeneration and Tau pathology (69). We carefully
investigated the impact of chronic SYK inhibition on neuroin-
flammation in Tg Tau P301S mice by analyzing the levels of
various pro-inflammatory cytokines and by quantifying Iba-1
and iNOS levels as markers of microgliosis (70, 71), as well as
GFAP tomeasure astrogliosis (72). We found that Iba-1, iNOS,
and various pro-inflammatory cytokine levels were markedly
increased in Tg Tau P301S mice compared with WT litter-
mates, whereas GFAP levels were unchanged. Chronic SYK
inhibition appeared to significantly reduce Iba-1, iNOS, and
pro-inflammatory cytokine levels in Tg Tau P301S mice sug-
gesting that SYK plays a key role in the induction of neuroin-
flammation byTaupathogenic species. Pro-inflammatory cyto-
kines produced by activated microglia have been shown to
promote Tau hyperphosphorylation (73, 74), and therefore,
SYK inhibition by directly targeting the activation of microglia
could also contribute to the decreased Tau hyperphosphoryla-
tion observed.
Several studies have linked neuroinflammation and a deficit
of autophagy in the context of neurodegenerative diseases. It
has been shown, for example, that mTOR or S6K inhibition by
rapamycin or PF4708671, respectively, prevents neuroinflam-
mation in a mouse model of cerebral palsy (75). In that mouse
model, the mice were subjected to hypoxia–ischemia and LPS-
induced inflammation on day 6 after birth. Zheng et al. (76)
showed that 5 mg/kg LPS injected intraperitoneally into
C57BL/6J mice at 3 and 16 months of age not only leads to
increased neuroinflammation but also to an autophagic impair-
ment. Zhou et al. (77) demonstrated that GSK-3 inhibition
suppressed neuroinflammation in the cortices of rats subjected
to ischemic brain injury by activating autophagy. In another
study, it was observed that neuroinflammation can block the
autophagic flux in rats subjected to stress-induced hyperten-
sion (67). It has also been suggested that glial cells play a major
role in the development of autophagy deficits observed in HIV-
associated dementia (78). In conclusion, these studies suggest
that a pathological disruption of autophagy can cause an initi-
ation or exacerbation of neuroinflammation, and conversely,
neuroinflammation can induce an autophagic deficit further
contributing to neurodegeneration. Our data show that SYK is
involved in both the regulation of autophagy as well as neuro-
inflammation and suggest that SYK may represent an impor-
tant therapeutic target for the treatment of neurodegenerative
proteinopathies.We found increased LAMP-1 levels in Tg Tau
P301S compared with WT littermates, which could be indica-
tive of a lysosomal defect in Tg Tau P301S. Interestingly,
LAMP-1 levels were reduced in Tg Tau P301S mice following
SYK inhibition, which could suggest that lysosomal functions
were also improved by the treatment. Bain et al. (79) found that
in some cases the pathological mechanism in FTLD–Tau may
be attributed to lysosomal deficiencies and impaired transport,
as LAMP-1 levels were increased suggesting the presence of
more lysosomes. They concluded that FTLD cases with an
underlying granulinmutation showTARDNA-binding protein
(TDP-43) aggregates because of a lysosomal dysfunction
(impaired degradation) rather than a lysosomal deficiency (lack
of lysosomes). In our study, we show that Tg Tau P301S mice
exhibit elevated levels of LAMP-1, along with increased Tau
levels compared with WT littermates. Because LAMP-1 levels
are increased and suggest higher numbers of lysosomes or
increased lysosomal surface area, a lysosomal defect or a dys-
functional transport, as suggested by Bain et al. (79), could also
contribute to the accumulation of Tau in TgTau P301Smice. It
is possible that the increased LAMP-1 levels observed inTgTau
P301S mice represent a compensatory mechanism, initiated to
counteract the lysosomal dysfunction. Interestingly, the treat-
ment with the SYK inhibitor decreased Tau, as well as LAMP-1
levels significantly, suggesting an improvement of lysosomal
functions. The analysis of the ratio of LC3-II/I in stable SYK
knockdown cells alone and in the presence of the lysosome
inhibitor CQ also indicate a possible role of SYK in lysosomal
degradation. The role of SYK in lysosomal functions will need
to be further delineated in future experiments.
The data presented in this study illustrate the dual role of
SYK as a regulator of neuroinflammation and autophagy in
the central nervous system. The observations made in this
study not only provide further evidence for an important role
of SYK in the pathogenesis of AD and the development of
Tau pathologies but also demonstrate that pharmacological
SYK inhibition may represent a promising therapeutic strat-
egy for the treatment of AD and other neurodegenerative
proteinopathies.
Experimental procedures
Animals
All mice were maintained under specific pathogen-free con-
ditions in ventilated racks in the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC) accredited vivarium of the Roskamp Institute. All
experiments involvingmicewere reviewed and approved by the
Institutional Animal Care and Use Committee of the Roskamp
Institute before implementation and were conducted in com-
pliancewith theNational Institutes ofHealthGuidelines for the
Care and Use of Laboratory Animals. Tg Tau P301S (51) mice
were obtained from The Jackson Laboratory and were bred
with C57BL/6J mice to produce the Tg Tau P301S and WT
littermates used in this study.
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In vivo treatment
The 30-week-old Tg Tau P301S mice and wildtype (WT)
littermates were injected with either PBS (vehicle) or 20 mg/kg
of the SYK inhibitor BAY61 5 consecutive days per week for a
total of 12 weeks. 45 animals were treated in total (WT-PBS
(n  11), WT-BAY61 (n  11), Tg Tau P301S–PBS (n  11),
and Tg Tau P301S–BAY61 (n  12)). The 2-(7-(3,4-dimeth-
oxyphenyl)imidazo[1,2-c]pyrimidin-5-ylamino) nicotinamide
hydrochloride hydrate (BAY61-3606) was synthesized as
described previously (80). The identity and purity of the com-
pound obtained were analyzed by tandem mass spectroscopy
(MS (ESI, positive ion) m/z 391.1 (M 1)). The activity of the
synthesized BAY61 was further compared against a batch of
BAY61 obtained by a commercial vendor (Sigma) by assessing
its potency for inhibiting p65NFB and STAT3 phosphoryla-
tion induced byTNF in SH-SY5Y cells as described previously
(data not shown) (25).
Behavioral analysis
Motor performance was assessed using a Rotarod apparatus
every 14 days. The mice were placed onto a horizontally-ori-
ented rotating cylinder. The baseline level was set to 5 rpm. The
speed of the rotation of the cylinder was set up to increase to 50
rpm within 1 min. The latency to fall was measured in seconds.
Each mouse underwent three trials per day, and the average
latency to fall was calculated. Mice showing signs of partial
paralysis of the hind limbs were excluded from the behavioral
assessments.
Tissue processing
All mice were humanely euthanized, and their brains were
collected. The right hemisphere was snap-frozen in liquid
nitrogen and stored at80 °C until processing. The method of
euthanasia used follows the American Veterinary Medical
Association (AVMA) guidelines for the euthanasia of animals.
Briefly, mice were rendered unconscious through inhalation of
5% isoflurane in oxygen using a vaporizer and a gas chamber.
While under anesthesia, after verifying the absence of reflexes,
mice were euthanatized by exsanguination (blood was with-
drawn from cardiac puncture).
The right hemispheres were homogenized in Mammalian
Protein Extraction Reagent (M-PERTM, Thermo Fisher Scien-
tific) containing Halt protease and phosphatase single use
inhibitor/EDTA (Thermo Fisher Scientific) and 1 mM PMSF.
Brain homogenates were centrifuged at 4 °C, 21,817 g for 30
min. The supernatant (detergent-soluble fraction) was col-
lected and stored at 80 °C until being assayed for total Tau
and phosphorylated Tau as described below. The pellet (deter-
gent-insoluble fraction) was resuspended by sonication in
M-PER (1:1 v/v). A portion of this detergent-insoluble fraction
was treated with an equal volume of 5 M guanidine isothiocya-
nate to dissociate and re-solubilize Tau aggregates and to quan-
tify the amount of detergent-insoluble total Tau and phosphor-
ylated Tau at multiple epitopes as described below. The
remaining portion of the detergent-insoluble fraction was used
to assess the levels of Tau oligomers and Tau pathogenic con-
formers under native conditions as described below.
Cell culture
SH-SY5Y cells were purchased from American Type Cul-
ture Collection (Manassas, VA). SH-SY5Y cells were grown
in Dulbecco’s modified Eagle’s medium/F-12 medium
(Thermo Fisher Scientific) supplemented with 10% fetal
bovine serum (Thermo Fisher Scientific), GlutaMAX, and
1% penicillin/streptomycin/fungizone.
Cell culture treatments
SH-SY5Y cells were treated in 500 l of medium for 24 h
using 24-well cell culture plates. The cells were treated with the
following inhibitors/activators: SYK inhibitor BAY61 (5–10
M, Sigma), Akt activator SC79 (20 M, Sigma), mTOR activa-
tor MHY1485 (4–12 M, Sigma), mTOR inhibitor KU0063794
(1–2 M, Sigma), S6K inhibitor PF4708671 (5–10 M, Tocris),
and lysosomal inhibitor CQ (100–200 M, Tocris).
SH-SY5Y differentiation
SH-SY5Y cells were differentiated as described previously by
Encinas et al. (28). Briefly, SH-SY5Y cells were seeded into
24-well plates and treated with 10 M retinoic acid in media
containing 15% fetal bovine serum for 5 days. Subsequently, the
cells were treated with 50 ng/ml BDNF for 7 days in media
containing no serum.
Puromycin incorporation assay
To investigate the possible impact of SYK inhibition on pro-
tein synthesis, we used the SUnSET technique (43). This tech-
nique involves the use of the antibiotic puromycin (a structural
analog of tyrosyl-tRNA), and anti-puromycin antibodies to
detect the amount of puromycin incorporation into nascent
peptide chains. Incorporation of puromycin into nascent poly-
peptides causes termination. Although a high concentration of
puromycin is toxic because it can inactivate translation, at low
concentrations it provides an accurate snapshot of protein syn-
thesis without causing lethality. Confluent SH-SY5Y cells were
treatedwith BAY61 and PF4708671 for 24 h andwith cyclohex-
imide for 5 h. Cells were then treated for 1 h with 10 g/ml
puromycin and lysed in ice-coldM-PER (Thermo Fisher Scien-
tific) containing Halt protease and phosphatase single use
inhibitor/EDTA (Thermo Fisher Scientific) and 1 mM PMSF.
Levels of newly synthesized proteins containing puromycin
were then detected byWestern blotting using an anti-puromy-
cin antibody (1:1000 dilution, Millipore Sigma).
Immunoprecipitation (IP)
Following the SUnSET technique, cell lysates were centri-
fuged at 16,000  g for 15 min at 4 °C to remove the insoluble
fractions. The resulting supernatants were subjected to IP with
2 g/ml anti-puromycin (Millipore Sigma) overnight at 4 °C.
Then, 20 l of protein A-magnetic beads (Thermo Fisher Sci-
entific) were added for 2 h at 4 °C. The beads were carefully
washed, and the proteins were eluted with reducing 2 Laem-
mli sample buffer (Bio-Rad) at 95 °C for 5 min. The samples
were then analyzed by Western blotting.
Quantitative RT-PCR
Total RNA was extracted from SH-SY5Y cells treated with
DMSO or BAY61 using the TRIzol reagent (Invitrogen). RNA
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was reverse-transcribed into first-strand cDNA using the
SuperScriptTM III first-strand synthesis system (Invitrogen).
Quantitative real-time PCR (qPCR) was performed with
ssoAdvancedTM Universal SYBR Green Supermix (Bio-Rad)
and analyzed on a CFX96 TouchTM Real-Time PCR Detection
System (Bio-Rad) as per the manufacturer’s instructions. The
mRNA levels in each sample were analyzed by normalizing the
threshold cycle (Ct) value to that of internal loading control,
-actin, employing the primer sets used for human total and 3R
Tau detection that have been described previously (81).
Generation of SYK knockdown SH-SY5Y cells
Short hairpin RNAs (shRNAs) were used to stably knock
down SYK gene expression in SH-SY5Y cells. GIPZ lentiviral
vectors expressing SYK-specific shRNAs (25) or nonsense con-
trol shRNAswere purchased fromOrigene. For stable transfec-
tion, SH-SY5Y cells were grown on 6-well plates until reaching
70–80% confluence and transfected with shRNA plasmids
using Lipofectamine 2000 (Invitrogen). After 48 h, transfected
cells were placed into fresh medium in the presence of 1 g/ml
puromycin for selection. After 14 days, the resistant cells were
trypsinized and expanded. The knockdown efficiency of SYK
was confirmed by Western blotting using antibodies against
SYK (4D10, Santa Cruz Biotechnology).
Immunoblotting
Western blots were performed as described previously (25,
26). Briefly, SH-SY5Y cells were cultured in 24-well plates,
treated for 24 h, and subsequently lysed with mammalian pro-
tein extraction reagent (MPER, Thermo Fisher Scientific) con-
taining Halt protease and phosphatase single use inhibitor/
EDTA (Thermo Fisher Scientific) and 1 mM PMSF. Proteins of
cell lysates were separated by 10% Tris-glycine–SDS-PAGE
using 1-mm Criterion TGX gels (Bio-Rad) and electrotrans-
ferred onto 0.2-mpolyvinylidene difluoride membranes (Bio-
Rad). For dot blots, 3 l of each sample were pipetted onto a
nitrocellulose membrane (pore size 45 m, Bio-Rad). Mem-
braneswere blocked inTBS containing 5%nonfat driedmilk for
1 h and were hybridized with the primary antibodies (anti-SYK
(4D10), 1:1000, Santa Cruz Biotechnology), anti-p-Tau Ser-
396/404 (PHF-1, 1:1000, Dr. Peter Davies’ lab), anti-t-Tau
(DA9, 1:1000, Dr. Peter Davies’ lab), anti-p-Tau Ser-202 (CP13,
1:1000,Dr. PeterDavies’ lab), anti-p-TauThr-231 (RZ3, 1:1000,
Dr. Peter Davies’ lab), anti-conformer-Tau (MC1, 1:1000, Dr.
PeterDavies’ lab), anti-oligomeric-Tau (TOC1, 1:1000,Dr. Les-
ter Binder’s lab) anti-p-SYK (Tyr-525/526), anti-p-mTOR (Ser-
2448), anti-p-S6K (Thr-389/Thr-412), anti-p-Akt (Ser-473),
anti-LC3b, anti-actin, anti-NeuN, anti-LAMP-1, anti-iNOS (all
1:1000, Cell Signaling), anti-GFAP (1:5000, DAKO), anti-Iba1
(1:1000, Abcam, MA), and anti--tubulin (1:1000, BD Biosci-
ences) overnight at 4 °C. Subsequently, the membranes were
incubated for 1 h in horseradish peroxidase–conjugated anti-
mouse or anti-rabbit secondary antibody (1:1000, Cell Signal-
ing). Western blottings and dot blots were visualized using
chemiluminescence (Super SignalWest FemtoMaximum Sen-
sitivity Substrate, ThermoFisher Scientific). Signalswere quan-
tified using ChemiDoc XRS (Bio-Rad), and densitometric anal-
yses were performed using Quantity One (Bio-Rad) image
analysis software.
Total protein concentration (BCA)
Total protein levels of in vivo samples were determined using
the Pierce BCA protein assay kit (Thermo Fisher Scientific).
The samples were prepared and measured as directed by the
manufacturer’s handbook.
ELISA for PSD-95 and cytokine levels
For quantification of in vivo PSD-95 and cytokine levels, the
MESO QuickPlex SQ 120 and the appropriate ELISA kits were
used (Meso Scale Diagnostics). The samples were prepared and
measured as directed by the manufacturer’s instructions. Then
16 wells were used for the standard. 10 samples (brain homo-
genates) from each treatment group were randomly selected.
The values for all brain samples were normalized to total pro-
tein level as determined by the BCA method.
Statistical analyses
The data were analyzed and plotted with GraphPad Prism
(GraphPad Software, Inc.). The Shapiro-Wilk test for normality
was used to test for Gaussian distribution. Statistical signifi-
cance was determined by either ANOVA (for comparisons of
three or more groups), two-way ANOVA (behavioral test), or t
tests (SYK knockdown) or the nonparametric Kruskal-Wallis
(Cytokine ELISA), where appropriate for data that were not
normally distributed. The ROUT test (Q 1%)was used for the
identification or rejection of statistical outliers. All data are pre-
sented as mean S.E., and p 0.05 was considered significant
(*, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001).
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